China SXT Pharmaceuticals, Inc. — Form 20-F Summary
Reporting period: Fiscal year ended March 31, 2022, compared primarily with fiscal year ended March 31, 2021. The requested “2021 Q4” period does not match the filing, which is an annual report rather than a quarterly filing. Financial statements are prepared under U.S. GAAP and consolidate the Chinese operating entity through contractual VIE arrangements.
Business Context
China SXT is a British Virgin Islands holding company whose operations are conducted principally in China through Taizhou Suxuantang, a variable interest entity. The company researches, manufactures and sells traditional Chinese medicine pieces and related products, including Advanced TCMP, Fine TCMP, Regular TCMP and TCM Homologous Supplements. Advanced TCMP represented approximately 44.7% of reported revenue in fiscal 2022.
Financial Performance and Position
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Revenue | $2.602 million | $4.778 million | Down 46% |
| Gross profit | $1.252 million | $2.840 million | Down 56% |
| Gross margin | 48.1% | 59.4% | Down 11.3 percentage points |
| Operating loss | $5.190 million | $2.197 million | Loss increased 136% |
| Net loss | $5.736 million | $2.748 million | Loss increased 109% |
| Net loss per share | $5.517 | $3.819 | Loss increased |
| Operating cash flow | $268,293 provided | $1.317 million used | Improved by $1.585 million |
| Investing cash flow | $46,909 used | $5.806 million used | Lower spending |
| Financing cash flow | $1.595 million provided | $12.409 million provided | Lower external funding |
Revenue declined across all product categories: Advanced TCMP fell 34% to $1.163 million, Fine TCMP fell 31% to $400,000, Regular TCMP fell 45% to $793,000, and TCMHS fell 75% to $246,000. Management attributed the decline primarily to COVID-19 lockdowns and the ongoing renewal process for the company’s GMP certificate.
General and administrative expenses increased 60% to $5.517 million, including approximately $2.334 million of equity incentive compensation and higher bad-debt provisions. Selling expenses declined 42% to $925,000, broadly reflecting lower revenue and marketing activity.
At March 31, 2022, cash and cash equivalents were $15.524 million, restricted cash was $45,297, total current assets were $22.452 million and total current liabilities were $17.122 million. Working capital was approximately $5.330 million. Accounts receivable, net, was $3.333 million, after a $762,992 allowance for doubtful accounts.
Debt, Liquidity and Capital Resources
- The company had $11,404 of current bank loans and no non-current bank loans at year-end.
- A March 2022 convertible note had original principal of $2.805 million, a 6% stated interest rate, a 12-month maturity and a $2.035 million net carrying value at March 31, 2022. The note is convertible and may create substantial dilution.
- Amounts due to related parties totaled $8.696 million, including $5.529 million owed to Jiangsu Health Pharmaceutical Investment Co., Ltd. and $2.030 million owed to Jianping Zhou.
- Fiscal 2022 financing included $3.115 million of net public-offering proceeds and approximately $2.357 million of net proceeds from the convertible note, partially offset by $3.813 million of repayments to related parties.
- Management stated that existing cash and anticipated operating cash flows were sufficient for at least the next 12 months, but also disclosed that additional capital raising would likely be required in the near future.
Material Changes Versus the Prior Comparable Period
- Revenue fell 46%, while net loss more than doubled to $5.736 million.
- Gross margin contracted from 59.4% to 48.1%, reflecting lower utilization and the persistence of fixed manufacturing costs.
- Operating expenses increased 28%, driven primarily by general and administrative expenses and equity incentive compensation.
- Operating cash flow improved to a $268,293 inflow, largely because of collections and reductions in supplier advances and other current assets; this improvement occurred despite the larger reported net loss and is not evidence of operating profitability.
- Cash and cash equivalents increased from $13.333 million to $15.524 million, supported by equity and convertible-debt financing.
- Shares outstanding increased materially through the public offering, employee incentives and other financing activity. The company subsequently completed a one-for-twenty reverse split effective in May 2022; share figures in the filing are generally presented on a post-split basis unless otherwise noted.
Outlook, Commentary, Risks and Unusual Items
- No quantitative revenue, earnings or margin guidance was provided.
- COVID-19-related lockdowns and logistics disruptions in China, particularly Jiangsu and other provinces, negatively affected product deliveries and fiscal 2022 revenue. The duration and severity of these effects remained uncertain.
- The company identified limited working capital and a likely need for additional financing. Future equity or convertible financing could materially dilute existing shareholders or create senior claims.
- The company operates through VIE contractual arrangements rather than direct ownership of Taizhou Suxuantang. The enforceability of these arrangements and the ability to transfer economic benefits from China to the offshore parent remain subject to PRC regulatory and legal uncertainty.
- At March 31, 2022, the company had a $9.465 million long-term deposit related to a potential acquisition that had not been approved or rejected and remained subject to legal and financial due diligence. It also reported an overdue $1.581 million loan receivable expected to be collected by September 30, 2022.
- The company provided guarantees for related-party borrowings totaling approximately $978,000 and disclosed an older guarantee related to a $914,928 obligation of Jianping Zhou. No payments had been made under the guarantees during fiscal 2022.
- Management concluded that disclosure controls and internal control over financial reporting were not effective as of March 31, 2022. Reported weaknesses included insufficient U.S. GAAP-capable accounting personnel, inadequate training and insufficient segregation of duties. The auditor was not engaged to provide an ICFR attestation.
- The company does not maintain product liability, business interruption or key-person insurance and does not expect to pay dividends in the foreseeable future.
- The auditor was PCAOB-registered and located in Denver, but the filing highlights continuing HFCA-related risks concerning access to audit work papers and potential future trading restrictions or delisting.
Most Important Facts for Investors to Verify
- Whether revenue and production volumes recover after COVID-19 restrictions and completion of the GMP certificate renewal process.
- The repayment, conversion or dilution impact of the $2.805 million convertible note and any subsequent redemptions or share issuances.
- The collectability and timing of the $1.581 million overdue loan receivable and the $9.465 million acquisition deposit.
- The terms, maturity and repayment expectations for the $8.696 million of related-party balances and the related-party guarantees.
- Progress in remediating the disclosed material weaknesses in disclosure controls and internal control over financial reporting.
- The legal and regulatory status of the VIE structure, PRC permissions for overseas-listed companies and any developments affecting capital transfers or dividend remittances.
- Post-filing share counts, reverse-split adjustments, equity incentive issuances and potential dilution from warrants and convertible securities.